Interpace Biosciences, Inc. ("Interpace” or the "Company”) (OTCQX: IDXG) today announced preliminary financial and business results for the fiscal year and fourth quarter ended December 31, 2024.

Goldman Sachs analyst Matthew Sykes downgraded Cytek Biosciences Inc (NASDAQ:CTKB) stock rating from Buy to Sell and reduced the price target to $4.50 from the previous $7.00. The downgrade reflects ...

Report with the AI impact on market trends - The global genomics market size is estimated to grow by USD 5.21 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR ...